...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma
【24h】

siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma

机译:靶向MDR1的siRNA逆转对阿霉素耐药的人肝细胞癌裸鼠模型的多药耐药性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aim: To investigate the effects of vector-based small interfering RNA (siRNA) targeting MDR1 on the reversal of multidrug resistance in a mouse model of doxorubicin (DOX)-resistant human hepatocellular carcinoma. Materials and Methods: Three siRNAs plasmid vectors (MDR1 siRNA1, MDR1 siRNA2 and MDR1 siRNA3) targeting MDR1 were constructed and transfected into DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells. The expression of MDR1 mRNA and P-glycoprotein (P-gp) was detected with RT-PCR and western blotting, respectively. A nude mouse model of DOX-resistance was established with untransfected Bel-7402/ADM or Bel-7402/ADM transfected with MDR1 siRNA (Bel-7402/ADMsi). The nude mice with tumors from untransfected Bel-7402/ADM cells were treated with either saline (Group 1); intravenous DOX (Group 2); or the combination of intra-tumoral MDR1 siRNA and intravenous DOX (Group 3). The nude mice with tumors from Bel-7402/ADMsi cells were treated with intravenous DOX (Group 4). DOX and MDR1 siRNA were administered twice a week at 20 mg/kg/dose and 9.8 mg/kg/dose, respectively. Tumor growth was measured to assess reversal of multidrug resistance by MDR1 siRNA. Results: MDRl mRNA and P-gp expression of Bel-7402/ADM cells was reduced by transfection of three siRNAs with different silencing efficiency (p<0.05). DOX treatment (Group 4) resulted in significant reduction in tumor size in the Bel-7402/ADMsi tumor model (p<0.05), indicating reversal of multidrug resistance in tumor by MDR1 siRNA. However, the combination treatment of intratumoral MDR1 siRNA and DOX (Group 3) showed no significant anti-tumor efficacy in the untransfected Bel-7402/ADM (p>0.05) tumor model, suggesting poor in vivo transfection efficiency of MDR1 siRNA. Analysis of the tumor samples showed the reduced expression level of MDR1 mRNA and P-gp was due to efficacy of MDR1 siRNA. Conclusion: In vitro transfection of siRNAs' vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model.
机译:目的:研究靶向MDR1的基于载体的小干扰RNA(siRNA)对耐阿霉素(DOX)的人肝细胞癌小鼠模型中多药耐药性逆转的影响。材料与方法:构建靶向MDR1的三种siRNA质粒载体(MDR1,siRNA1,MDR1,siRNA2和MDR1 siRNA3),并将其转染到抗DOX的人肝细胞癌Bel-7402 / ADM细胞中。 RT-PCR和Western blotting检测MDR1 mRNA和P-糖蛋白(P-gp)的表达。用未转染的MDR1 siRNA(Bel-7402 / ADMsi)转染的Bel-7402 / ADM或Bel-7402 / ADM建立抗DOX的裸鼠模型。用两种盐水(第1组)处理裸鼠,其中裸鼠的肿瘤来自未转染的Bel-7402 / ADM细胞。静脉DOX(组2);或肿瘤内MDR1 siRNA和静脉内DOX的组合(第3组)。将具有Bel-7402 / ADMsi细胞肿瘤的裸鼠用静脉内DOX治疗(第4组)。每周两次分别以20 mg / kg /剂量和9.8 mg / kg /剂量施用DOX和MDR1 siRNA。测量肿瘤生长以评估MDR1 siRNA逆转多药耐药性。结果:通过转染三种沉默效率不同的siRNA,降低了Bel-7402 / ADM细胞的MDR1 mRNA和P-gp表达(p <0.05)。 DOX治疗(第4组)导致Bel-7402 / ADMsi肿瘤模型的肿瘤大小显着减少(p <0.05),表明MDR1 siRNA逆转了肿瘤的多药耐药性。然而,在未转染的Bel-7402 / ADM(p> 0.05)肿瘤模型中,肿瘤内MDR1 siRNA和DOX(第3组)的联合治疗未显示出显着的抗肿瘤功效,表明MDR1 siRNA的体内转染效率较差。肿瘤样品的分析显示,MDR1 mRNA和P-gp的表达水平降低归因于MDR1 siRNA的功效。结论:靶向MDR1基因的siRNA载体的体外转染可有效沉默DOX耐药人肝癌细胞Bel-7402 / ADM细胞中MDR1 mRNA和P-gp表达,从而导致异种移植肿瘤模型对DOX的多药耐药性逆转。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号